Canada Markets close in 2 hrs 4 mins

Timber Pharmaceuticals, Inc. (TMBR)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.7199+0.0170 (+2.42%)
As of 1:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.7029
Open0.7000
Bid0.7101 x 3000
Ask0.7130 x 1800
Day's Range0.6902 - 0.7200
52 Week Range0.6650 - 3.6500
Volume302,109
Avg. Volume785,110
Market Cap26.523M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

    Data demonstrate reduction in targeted and overall severity of CI in patients treated with topical IPEG™ TMB-001 (topical isotretinoin) Company planning for end-of-Phase 2 meeting with FDA in the beginning of 2022 Phase 3 study is expected to begin in Q2 2022 Basking Ridge, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatme

  • GlobeNewswire

    Timber Pharmaceuticals Presents at EADV’s 30th Anniversary Congress

    Basking Ridge, N.J., Oct. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it is presenting at the European Academy of Dermatology and Venereology’s (EADV) 30th anniversary congress being held virtually from September 29-October 2, 2021. The topic of the Company’s

  • GlobeNewswire

    Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    BASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The Conference will be held virtually with all participants joining remotely from September 13th - 15th, 2021.